Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist
View Patent ↗This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5 + CD4 + target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 + cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5 + CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
1. A method of potentiating HIV-1 inhibitory activity of a small molecule CCR5 receptor antagonist in an HIV-1-infected subject who has been administered, or will be administered, the small molecule CCR5 receptor antagonist in the treatment of the subject's HIV-1 infection, comprising administering to the subject an HIV-1 inhibitory amount of an anti-CCR5 receptor monoclonal antibody, wherein the amounts of the anti-CCR5 receptor monoclonal antibody and the small molecule CCR5 receptor antagonist combined, produces a synergistic antiviral effect on treating the HIV-1 infection, thereby potentiating the HIV-1 inhibitory activity of the small molecule CCR5 receptor antagonist, wherein the anti-CCR5 receptor monoclonal antibody is PRO 140, said PRO 140 comprising (i) two light chains, each light chain comprising the expression product of the plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the expression product of either the plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or the plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099) and wherein the small molecule CCR5 receptor antagonist is (1-[(4,6-dimethyl-5-pyrimidinyl) carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyli-4-methylpiperidine) (UK-427,857) having the structure:
TAK-779 having the structure:
where Y=-CH 2 , X=-Cl, R1=-CH 3
TAK-652 having the structure:
or GW873140.
2. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is a humanized, human, or chimeric antibody.
3. The method of claim 1 , wherein each heavy chain comprises the expression product of the plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098).
4. The method of claim 1 , wherein the PRO 140 is administered via intravenous infusion.
5. The method of claim 1 , wherein the PRO 140 is administered via subcutaneous injection.
6. The method of claim 1 , wherein the small molecule CCR5 receptor antagonist is orally administered.
7. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is administered concurrently with administration of the small molecule CCR5 receptor antagonist.
8. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is administered prior to administration of the small molecule CCR5 receptor antagonist.
9. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is administered subsequent to administration of the small molecule CCR5 receptor antagonist.
10. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is administered in a dose of 0.01 mg per kg body weight to 50 mg per kg body weight of the subject.
11. The method of claim 10 , wherein the anti-CCR5 receptor monoclonal antibody is administered in a dose of 0.05 mg per kg body weight to 25 mg per kg body weight of the subject.
12. The method of claim 10 , wherein the anti-CCR5 receptor monoclonal antibody is administered in a dose of 0.1 mg per kg body weight to 10 mg per kg body weight of the subject.
13. The method of claim 10 , wherein the anti-CCR5 receptor monoclonal antibody is administered in a dose of 0.5 mg per kg body weight to 5 mg per kg body weight of the subject.
14. The method of claim 1 , wherein the synergistic antiviral effect comprises a reduction in HIV-1 viral load in the HIV-1-infected subject by at least 90% following administration of the antibody, and wherein the reduction is maintained for at least two weeks.
15. The method of claim 1 , wherein the anti-CCR5 receptor monoclonal antibody is to be administered at a predefined interval, and the predefined interval is at least once weekly, every two to four weeks, every two weeks, every four weeks, or at least once monthly.
16. The method of claim 1 , wherein the small molecule CCR5 receptor antagonist is (1-[(4,6-dimethyl-5-pyrimidinyl) carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyli-4-methylpiperidine) (UK-427,857) having the structure:
17. The method of claim 1 , wherein the small molecule CCR5 receptor antagonist is TAK-779 having the structure:
where Y=—CH 2 , X=—Cl, R1=—CH 3
18. The method of claim 1 , wherein the small molecule CCR5 receptor antagonist is TAK-652 having the structure:
19. The method of claim 1 , wherein the small molecule CCR5 receptor antagonist is GW873140.